225Ac labeled anti-HER2 2Rs15d sdAb as a potential therapeutic for targeted alpha therapy – an in vitro and in vivo evaluation

Magdalena  Rodak; Yana Dekempeneer; Maria Wojewodzka; Tony Lahoutte; Frank Bruchertseifer; Alfred Morgenstern; Matthias D'Huyvetter; Marek Pruszynski

doi:10.1016/S0969-8051(21)00317-6

225Ac labeled anti-HER2 2Rs15d sdAb as a potential therapeutic for targeted alpha therapy – an in vitro and in vivo evaluation

Magdalena Rodak, Yana Dekempeneer, Maria Wojewodzka, Tony Lahoutte, Frank Bruchertseifer, Alfred Morgenstern, Matthias D'Huyvetter, Marek Pruszynski

Research output › peer-review

Abstract

Human epidermal growth factor receptor type 2 (HER2) over expression cause more aggressive form of cancer, metastatic activity and chemo-resistance. Single-domain antibody fragments (sdAbs) are the smallest antibody-derived fragments with beneficial pharmacokinetic properties for molecular imaging and Targeted Radionuclide Therapy (TRT). Therefore, HER2-targeting sdAbs are very attractive vectors for TRT, especially when labeled with .-particle emitters, due to their small size (~15kDa), nM-range affinity, low immunogenicity, rapid clearance from blood and ease of tumor penetration. The goal of this study was to evaluate the therapeutic potential of the anti-HER2 sdAb 2Rs15d labeled with 225Ac

Original language	English
Title of host publication	Nuclear Medicine and Biology
Publisher	Elsevier
Pages	S33
Number of pages	1
Volume	97-97
DOIs	https://doi.org/10.1016/S0969-8051(21)00317-6
State	Published - 21 May 2021

Publication series

Name	Nuclear Medicine and Biology
Publisher	Elsevier
Number	S33
Volume	96-97
ISSN (Electronic)	0969-8051

Access to Document

10.1016/S0969-8051(21)00317-6License: Unspecified

Cite this

Rodak, M., Dekempeneer, Y., Wojewodzka, M., Lahoutte, T., Bruchertseifer, F., Morgenstern, A., D'Huyvetter, M., & Pruszynski, M. (2021). 225Ac labeled anti-HER2 2Rs15d sdAb as a potential therapeutic for targeted alpha therapy – an in vitro and in vivo evaluation. In Nuclear Medicine and Biology (Vol. 97-97, pp. S33). Article SSP-30 (Nuclear Medicine and Biology; Vol. 96-97, No. S33). Elsevier. https://doi.org/10.1016/S0969-8051(21)00317-6

@inproceedings{39d3d6d8cbbe472db9d5ee878fd2311c,

title = "225Ac labeled anti-HER2 2Rs15d sdAb as a potential therapeutic for targeted alpha therapy – an in vitro and in vivo evaluation",

abstract = "Human epidermal growth factor receptor type 2 (HER2) over expression cause more aggressive form of cancer, metastatic activity and chemo-resistance. Single-domain antibody fragments (sdAbs) are the smallest antibody-derived fragments with beneficial pharmacokinetic properties for molecular imaging and Targeted Radionuclide Therapy (TRT). Therefore, HER2-targeting sdAbs are very attractive vectors for TRT, especially when labeled with .-particle emitters, due to their small size (~15kDa), nM-range affinity, low immunogenicity, rapid clearance from blood and ease of tumor penetration. The goal of this study was to evaluate the therapeutic potential of the anti-HER2 sdAb 2Rs15d labeled with 225Ac",

keywords = "Radiopharmaceuticals, Therapy, Actinium, Nanobody",

author = "Magdalena Rodak and Yana Dekempeneer and Maria Wojewodzka and Tony Lahoutte and Frank Bruchertseifer and Alfred Morgenstern and Matthias D'Huyvetter and Marek Pruszynski",

note = "Score=3",

year = "2021",

month = may,

day = "21",

doi = "10.1016/S0969-8051(21)00317-6",

language = "English",

volume = "97-97",

series = "Nuclear Medicine and Biology",

publisher = "Elsevier",

number = "S33",

pages = "S33",

booktitle = "Nuclear Medicine and Biology",

address = "Netherlands",

}

Rodak, M, Dekempeneer, Y, Wojewodzka, M, Lahoutte, T, Bruchertseifer, F, Morgenstern, A, D'Huyvetter, M & Pruszynski, M 2021, 225Ac labeled anti-HER2 2Rs15d sdAb as a potential therapeutic for targeted alpha therapy – an in vitro and in vivo evaluation. in Nuclear Medicine and Biology. vol. 97-97, SSP-30, Nuclear Medicine and Biology, no. S33, vol. 96-97, Elsevier, pp. S33. https://doi.org/10.1016/S0969-8051(21)00317-6

TY - GEN

T1 - 225Ac labeled anti-HER2 2Rs15d sdAb as a potential therapeutic for targeted alpha therapy – an in vitro and in vivo evaluation

AU - Rodak, Magdalena

AU - Dekempeneer, Yana

AU - Wojewodzka, Maria

AU - Lahoutte, Tony

AU - Bruchertseifer, Frank

AU - Morgenstern, Alfred

AU - D'Huyvetter, Matthias

AU - Pruszynski, Marek

N1 - Score=3

PY - 2021/5/21

Y1 - 2021/5/21

N2 - Human epidermal growth factor receptor type 2 (HER2) over expression cause more aggressive form of cancer, metastatic activity and chemo-resistance. Single-domain antibody fragments (sdAbs) are the smallest antibody-derived fragments with beneficial pharmacokinetic properties for molecular imaging and Targeted Radionuclide Therapy (TRT). Therefore, HER2-targeting sdAbs are very attractive vectors for TRT, especially when labeled with .-particle emitters, due to their small size (~15kDa), nM-range affinity, low immunogenicity, rapid clearance from blood and ease of tumor penetration. The goal of this study was to evaluate the therapeutic potential of the anti-HER2 sdAb 2Rs15d labeled with 225Ac

AB - Human epidermal growth factor receptor type 2 (HER2) over expression cause more aggressive form of cancer, metastatic activity and chemo-resistance. Single-domain antibody fragments (sdAbs) are the smallest antibody-derived fragments with beneficial pharmacokinetic properties for molecular imaging and Targeted Radionuclide Therapy (TRT). Therefore, HER2-targeting sdAbs are very attractive vectors for TRT, especially when labeled with .-particle emitters, due to their small size (~15kDa), nM-range affinity, low immunogenicity, rapid clearance from blood and ease of tumor penetration. The goal of this study was to evaluate the therapeutic potential of the anti-HER2 sdAb 2Rs15d labeled with 225Ac

KW - Radiopharmaceuticals

KW - Therapy

KW - Actinium

KW - Nanobody

UR - https://ecm.sckcen.be/OTCS/llisapi.dll/open/48305603

U2 - 10.1016/S0969-8051(21)00317-6

DO - 10.1016/S0969-8051(21)00317-6

M3 - In-proceedings paper

VL - 97-97

T3 - Nuclear Medicine and Biology

SP - S33

BT - Nuclear Medicine and Biology

PB - Elsevier

ER -